Modifying PEST for Psoriatic Arthritis Screening (NCT06382051)
A Multicenter, Prospective, Study to Evaluate the Impact of Modifying the Validated Psoriasis Epidemiology Screening Tool (PEST) on the Potential Diagnosis of Psoriatic Arthritis in Adult Patients With Moderate-to-severe Plaque Psoriasis in Canada ("ScreenX")
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
Who can join: Review the eligibility criteria below.
Location: Novartis Investigative Site — Calgary, Alberta
Age range: 18 Years
🧪 Interventions in This Study
- PEST Screening group (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (30 Sites)
Showing the first 25 of 30 sites.
- Novartis Investigative Site — Calgary, Alberta
- Novartis Investigative Site — Edmonton, Alberta
- Novartis Investigative Site — Edmonton, Alberta
- Novartis Investigative Site — Kelowna, British Columbia
- Novartis Investigative Site — Surrey, British Columbia
- Novartis Investigative Site — Winnipeg, Manitoba
- Novartis Investigative Site — Fredericton, New Brunswick
- Novartis Investigative Site — Barrie, Ontario
- Novartis Investigative Site — Greater Sudbury, Ontario
- Novartis Investigative Site — Hamilton, Ontario
- Novartis Investigative Site — Hamilton, Ontario
- Novartis Investigative Site — Hamilton, Ontario
- Novartis Investigative Site — London, Ontario
- Novartis Investigative Site — London, Ontario
- Novartis Investigative Site — Markham, Ontario
- Novartis Investigative Site — Ottawa, Ontario
- Novartis Investigative Site — Richmond Hill, Ontario
- Novartis Investigative Site — Stoney Creek, Ontario
- Novartis Investigative Site — Toronto, Ontario
- Novartis Investigative Site — Toronto, Ontario
- Novartis Investigative Site — Waterloo, Ontario
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Québec, Quebec
📞 Contact the Study Coordinator
Phone: +41613241111
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Plaque Psoriasis
- A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis — Phoenix, Arizona
- Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis — Phoenix, Arizona
- A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis — Birmingham, Alabama
- Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects — Rogers, Arkansas
- Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis — Birmingham, Alabama
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) — Phoenix, Arizona
Explore by condition: All Plaque Psoriasis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.